Fabrazyme (Genzyme Corp)
Fabrazyme (Genzyme Corp) Brand names, Fabrazyme (Genzyme Corp) Analogs
Fabrazyme (Genzyme Corp) Brand Names Mixture
- No information avaliable
Fabrazyme (Genzyme Corp) Chemical_Formula
C2029H3080N544O587S27
Fabrazyme (Genzyme Corp) RX_link
http://www.rxlist.com/cgi/generic3/fabrazyme.htm
Fabrazyme (Genzyme Corp) fda sheet
Fabrazyme (Genzyme Corp) msds (material safety sheet)
Fabrazyme (Genzyme Corp) Synthesis Reference
No information avaliable
Fabrazyme (Genzyme Corp) Molecular Weight
45351.6
Fabrazyme (Genzyme Corp) Melting Point
No information avaliable
Fabrazyme (Genzyme Corp) H2O Solubility
No information avaliable
Fabrazyme (Genzyme Corp) State
Liquid
Fabrazyme (Genzyme Corp) LogP
-0.307
Fabrazyme (Genzyme Corp) Dosage Forms
Powder for solution
Fabrazyme (Genzyme Corp) Indication
For treatment of Fabry's disease (alpha-galactosidase A deficiency)
Fabrazyme (Genzyme Corp) Pharmacology
Used in the treatment of Fabry disease, an X-linked genetic disorder of glycosphingolipid metabolism. The disease is characterized by a deficiency of the lysosomal enzyme alpha-galactosidase A, which leads to progressive accumulation of glycosphingolipids, predominantly GL-3, in many body tissues. Clinical manifestations of Fabry disease include renal failure, cardiomyopathy, and cerebrovascular accidents. Fabrazyme is intended to provide an exogenous source of alpha-galactosidase A and to limit the accumulation of these glycolipids in the tissues.
Fabrazyme (Genzyme Corp) Absorption
No information avaliable
Fabrazyme (Genzyme Corp) side effects and Toxicity
No information avaliable
Fabrazyme (Genzyme Corp) Patient Information
BIOD00075.html
Fabrazyme (Genzyme Corp) Organisms Affected
Humans and other mammals
